Clinical trial · Expanded Access
Single-Patient Expanded Access Protocol - RNA-LP in a Patient With Recurrent Osteosarcoma
Single-Patient Expanded Access Treatment Protocol for Use of RNA Loaded Lipid Particles (RNA-LPs) in a Patient With Recurrent Osteosarcoma
NCT07560709CI-TRIAL-00110032no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
Treatment of a patient with recurrent osteosarcoma with personalized pp65/tumor mRNA RNA-LP under an individual patient expanded access protocol.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Osteosarcoma | Osteosarcoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pp65/tumor mRNA RNA-LP | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 15 Years
- Maximum age
- 17 Years
Show eligibility criteria text
Inclusion Criteria: * Participated in clinical trial * Received pp65 RNA-LPs alone and had pp65/tumor mRNA RNA-LP manufactured * Progressive disease prior to treatment with pp65/tumor mRNA RNA-LP Exclusion Criteria: • Diagnosis of recurrent OSA is not histopathologically confirmed (i.e. pseudoprogression)
References
Publications (0)
Data not yet available
No reference posted for this study.